文献速递胃肠外科围术期管理与 ERAS

减重手术长期结局:RYGB与袖状胃切除术的meta分析

Weighing the impact of bariatric surgery: A meta-analysis of long-term outcomes of Roux-en-Y gastric bypass and sleeve gastrectomy.
PubMed 文献 · Surgery · 2025-12-09

结果显示RYGB在20年随访时BMI降幅达-17.4 kg/m2,SG在10年时为-11.0 kg/m2;RYGB的糖尿病和高血压缓解率均优于SG,且SG的高血压缓解在10年时消失。

要点

  • RYGB长期减重效果优于SG,20年BMI降幅-17.4 kg/m2,SG 10年为-11.0 kg/m2。
  • RYGB糖尿病缓解率是SG的2.0倍,10年降幅分别为52.1%和23.9%。
  • SG组高血压患病率在10年时回归基线,而RYGB维持51.9%的降幅。

核心结论

  • RYGB和SG在术后10年以上均能有效减重并改善合并症,但RYGB减重更显著且合并症缓解更持久。

主要发现

  • RYGB在20年随访时BMI降幅为-17.4 kg/m2,SG在10年时为-11.0 kg/m2。
  • RYGB组10年糖尿病患病率降低52.1%,SG组降低23.9%。
  • RYGB组高血压患病率在10年和12年分别降低51.9%和26.0%,SG组10年时回归基线。
  • 对照组体重维持基线水平,糖尿病和高血压患病率在所有观察时间点持续增加。

关键数值与推荐

  • RYGB减重效果为SG的1.4倍,糖尿病缓解率为2.0倍。

临床怎么用

  • 对于追求更显著且持久的减重及代谢病缓解的肥胖患者,可优先考虑RYGB;SG在10年内有效但高血压缓解可能不持久。

局限性

  • 高血压数据稳健性较低,原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Obesity is the second-leading cause of preventable death in the United States and is known to be associated with serious health conditions, including cardiovascular disease, diabetes, and malignancy. The purpose of this meta-analysis was to aggregate the largest body of data on the long-term efficacy of Roux-en-Y gastric bypass and sleeve gastrectomy on weight reduction and comorbidity resolution in patients with obesity. METHODS: A meta-analysis was performed following the Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. Data on weight loss and prevalence diabetes and/or hypertension were aggregated per study protocol from those studies meeting inclusion criteria. Data were then analyzed and graphed with GraphPad Prism. RESULTS: Forty studies were included in this review, accounting for 51,055 patients. Baseline body mass index and prevalence rates of diabetes and hypertension were greatest in the surgical cohorts. Roux-en-Y gastric bypass was associated with maximal long-term body mass index reductions (-17.4 kg/m2) at 20-year follow-up, compared with (-11.0 kg/m2) at 10 years for sleeve gastrectomy. Both groups demonstrated a sustained decrease in the prevalence of diabetes at 10 years, 52.1% decrease for Roux-en-Y gastric bypass and 23.9% for sleeve. Although HTN data are less robust, Roux-en-Y gastric bypass maintains a 51.9% and 26.0% reduction in prevalence at 10 and 12 years, whereas sleeve gastrectomy returns to baseline prevalence of hypertension at 10 years. The medical and lifestyle management control group maintain baseline weight throughout the study period and demonstrate a consistent increase in diabetes and hypertension rates at all examined times. CONCLUSION: Sleeve gastrectomy and Roux-en-Y gastric bypass are effective in reducing weight and comorbidities beyond 10 years postoperatively, compared with minimal weight reduction and greater comorbidity prevalence in the control groups. Roux-en-Y gastric bypass produced more significant weight loss (1.4×) than sleeve gastrectomy, greater rates of diabetes reduction (2.0×), and sustained hypertension reduction, whereas this effect was lost for sleeve gastrectomy.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. Cunningham MH, Bloomfield GC, Chen MY, et al. Weighing the impact of bariatric surgery: A meta-analysis of long-term outcomes of Roux-en-Y gastric bypass and sleeve gastrectomy. Surgery. 2025. PMID: 41371191. doi:10.1016/j.surg.2025.109934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。